Sorafenib is an anticancer medicine approved by US FDA for the treatment of,
1. Unresectable hepatocellular carcinoma (HCC).
2. Advanced renal cell carcinoma (RCC).
DOSAGE AND ADMINISTRATION
The recommended daily dose of NOBOKIN is 400 mg twice daily without food (at least 1 hour before or 2 hours after a meal). Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.
Mechanism of Action
Sorafenib targets the adenosine triphosphate (ATP) binding site of multiple tyrosine kinase including vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3, FMS-like tyrosine kinase 3 (FLT3), platelet derived growth factor receptor (PDGF), fibroblast growth factor receptor 1 (FGFR1), FMS-like tyrosine kinase 3 (Flt3), c-Kit protein (KIT) and RET receptor tyrosine kinase. These receptor tyrosine kinasea are important for tumor angiogenesis, proliferation and metastatic progression.
Please see the full prescribing information for details.